ArticleBlood cancer journal2025

Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience.

Ricardo D Parrondo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.